Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun 1;25(11):3229-3238.
doi: 10.1158/1078-0432.CCR-18-2675. Epub 2019 Feb 18.

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Yael P Mossé  1   2 , Elizabeth Fox  3   2 , David T Teachey  3   2 , Joel M Reid  4 , Stephanie L Safgren  4 , Hernan Carol  5 , Richard B Lock  5 , Peter J Houghton  6 , Malcolm A Smith  7 , David Hall  8 , Donald A Barkauskas  8 , Mark Krailo  9 , Stephan D Voss  10 , Stacey L Berg  11 , Susan M Blaney  11 , Brenda J Weigel  10
Affiliations
Clinical Trial

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

Yael P Mossé et al. Clin Cancer Res. .

Abstract

Purpose: Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a potent and selective AAK inhibitor. In pediatric preclinical models, antitumor activity was observed in neuroblastoma, acute lymphoblastic leukemia, and sarcoma xenografts. We conducted a phase 2 trial of alisertib in pediatric patients with refractory or recurrent solid tumors or acute leukemias (NCT01154816).

Patients and methods: Alisertib (80 mg/m2/dose) was administered orally, daily for 7 days every 21 days. Pharmacogenomic (PG) evaluation for polymorphisms in the AURK gene and drug metabolizing enzymes (UGT1A1*28), and plasma pharmacokinetic studies (PK) were performed. Using a 2-stage design, patients were enrolled to 12 disease strata (10 solid tumor and 2 acute leukemia). Response was assessed after cycle 1, then every other cycle.

Results: A total of 139 children and adolescents (median age, 10 years) were enrolled, 137 were evaluable for response. Five objective responses were observed (2 complete responses and 3 partial responses). The most frequent toxicity was myelosuppression. The median alisertib trough concentration on day 4 was 1.3 μmol/L, exceeding the 1 μmol/L target trough concentration in 67% of patients. No correlations between PG or PK and toxicity were observed.

Conclusions: Despite alisertib activity in pediatric xenograft models and cogent pharmacokinetic-pharmacodynamic relationships in preclinical models and adults, the objective response rate in children and adolescents receiving single-agent alisertib was less than 5%.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure Statement: The authors declare no potential conflict of interest.

Figures

Figure 1.
Figure 1.
Sagittal and axial SPECT/CT images from 123I-MIBG examination performed at baseline, reporting periods (RP) 12 and 24; 123I-MIBG anterior projection planar images at baseline, RP10 and RP 20. Each reporting period is one cycle. Arrows indicate MIBG-avid neuroblastoma in the L3 vertebral body and proximal right femur. The other areas of MIBG positivity on planar imagines include physiologic uptake in liver, salivary glands, renal collecting system, GI tract, and excretion in bladder. Uptake projecting of the thorax at RP 10 and 10 is residual tracer at the port injection site.
Figure 2.
Figure 2.
Percentage of huCD45 cells in peripheral blood over time (A), and event-free survival curves (B) for ALL-8 engrafted NOD/SCID mice treated with alisertib at 10.4 mg/kg twice daily for 7 days (Schedule A, red), or twice daily for 5 days repeated for 3 weeks (Schedule B, blue) in relation to vehicle-treated controls (dotted line).
Figure 3.
Figure 3.
Percentage of huCD45+ cells in peripheral blood over time (A), and event-free survival curves (B) for ALL-19 engrafted NOD/SCID mice treated with alisertib at 10.4 mg/kg twice daily for 7 days (Schedule A, red), or twice daily for 5 days repeated for 3 weeks (Schedule B, blue) in relation to vehicle-treated controls (dotted line).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gautschi O, Heighway J, Mack PC, et al.: Aurora kinases as anticancer drug targets. Clinical cancer research : an official journal of the American Association for Cancer Research 14:1639–48, 2008 - PubMed
    1. Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2:21–32, 2001 - PubMed
    1. Lapenna S, Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nature reviews. Drug discovery 8:547–66, 2009 - PubMed
    1. Sen S, Zhou H, Zhang RD, et al.: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. Journal of the National Cancer Institute 94:1320–9, 2002 - PubMed
    1. Borges KS, Moreno DA, Martinelli CE Jr., et al.: Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurora kinases A and B is associated with a poor prognosis. Pediatr Blood Cancer 60:1809–16, 2013 - PubMed

Publication types

MeSH terms

Associated data